Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
First Claim
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence selected from SEQ ID NO:
- 24,wherein said cancer is selected from liver cancer, benign prostate hyperplasia, and prostate cancer.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Citations
20 Claims
-
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence selected from SEQ ID NO:
- 24,
wherein said cancer is selected from liver cancer, benign prostate hyperplasia, and prostate cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20)
- 24,
-
17. A method of eliciting an immune response in a patient who has liver cancer, benign prostate hyperplasia, or prostate cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence selected from SEQ ID NO:
- 24, thereby inducing a T-cell response to the liver cancer, benign prostate hyperplasia, or prostate cancer.
- View Dependent Claims (18, 19)
Specification